<DOC>
	<DOCNO>NCT00374907</DOCNO>
	<brief_summary>The purpose clinical research study learn whether Saxagliptin improve body 's ability make insulin low blood sugar people type 2 diabetes</brief_summary>
	<brief_title>A Study Assessing Saxagliptin Treatment Subjects With Type 2 Diabetes Who Are Not Controlled With Diet Exercise</brief_title>
	<detailed_description>All subject participate lead-in period , qualify subject continue short-term randomized treatment period . Subjects complete short-term period eligible enter long term extension period . Also , subject elevate blood sugar require additional medication blood sugar control eligible receive open-label metformin add onto blind study medication</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 diabetes mellitus Drug naive Hemoglobin A1c ( HbA1c ) ≥6.0 % ≤8.0 % Fasting Cpeptide ≥1.0 ng/mL Body mass index ≤40 kg/m² Recent cardiac cerebrovascular event Elevated serum creatinine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>